Anthracycline-induced acute cardiotoxicity in adults treated for leukaemia

Annals of Oncology

Volumn 12, Issue 7, 2001, Pages 963-966

  Dazzi, H ^a   Kaufmann, K ^a   Follath, F ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Anthracycline associated acute cardiotoxicity; Clinical symptoms; Pathological findings

Indexed keywords

AMSACRINE; ANTHRACYCLINE; CATECHOLAMINE; CYTARABINE; DAUNORUBICIN; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ETOPOSIDE; IDARUBICIN; LIDOCAINE; MITOXANTRONE; VINCRISTINE;

ACUTE DISEASE; ADULT; AGED; ARTICLE; AUTOPSY; CARDIOTOXICITY; CAUSE OF DEATH; CELL VACUOLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG SENSITIVITY; FEMALE; HEART DISEASE; HEART FAILURE; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART MUSCLE INJURY; HEART VENTRICLE HYPERTROPHY; HIGH RISK PATIENT; HUMAN; LEUKEMIA; MALE; MEDICAL RECORD; MICROSCOPY; PATHOLOGY; PERICARDIAL EFFUSION; PREDICTION; PRIORITY JOURNAL; RELIABILITY; RETROSPECTIVE STUDY; SWITZERLAND; SYMPTOMATOLOGY; UNIVERSITY HOSPITAL;

ACUTE DISEASE; ADULT; ANTIBIOTICS, ANTINEOPLASTIC; CARDIOMYOPATHIES; HUMANS; LEUKEMIA; MEDICAL RECORDS; RETROSPECTIVE STUDIES;

EID: 0034909855     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1011196910325     Document Type: Article

References (37)

1. Dose effect and structure function relationships in doxorubicin cardiomyopathy
2. Risk factors for doxorubicin-induced congestive heart failure
3. Clinical and morphological findings after anthracycline therapy
4. Adriamycin cardiotoxicity: A survey of 1273 Patients
5. Endomyocardial changes in anthracycline-treated patients with and without irradiation
6. Prospective study of cardiomyopathy induced by adjuvant doxorubicin therapy in patients with soft-tissue sarcomas
7. Anthracycline-induced cardiotoxicity
8. Acute arrhythmogenicity of doxorubicin administration
9. Overview of cardiac pathology in relation to anthracycline cardiotoxicity
10. Doxorubicin cardiomyopathy: Evaluation by phonocardiography, endomyocardial biopsy and cardiac catheterisation
11. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy
12. Doxorubicin-induced congestive heart failure in adults
13. Cardiac toxicity 4 to 20 years after completing anthracycline therapy
14. Functional myocardial impairment in children treated with anthracyclines for cancer
15. Electrocardio graphic changes after cancer therapy in children and young adults
16. Late cardiac effects of doxorubicin therapy for ALL in childhood
17. Early anthracycline cardiotoxicity
18. Early and delayed clinical cardiotoxicity of doxorubicin
19. A clinical pathologic analysis of adriamycin cardiotoxicity
20. Congestive heart failure due to adriamycin cardiotoxicity
21. Daunomycin-induced cardiotoxicity in children and adults
22. Age-related adriamycin cardiotoxicity in children
23. Daunorubicin cardiac toxicity in children with ALL
24. Cardiac function in wilms'tumor survivors
25. Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule
26. Ameliorating anthracycline cardiotoxicity in children with cancer: Clinical trials with dexrazoxane
27. Cytoprotective agents for anthracyclines
28. Left ventricular remodelling after acute myocardial infarction-solved and unsolved issues
29. Use of cardiac troponin T levels as an indicator of doxorubicin-induced cardiotoxicity
30. Cardiac troponin T and creatine kinase MB mass concentrations in children receiving anthracycline chemotherapy
31. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: Prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction
32. Structural remodelling of the heart by fibrous tissue: Role of circulating hormones and locally produced peptides
33. Doxorubicin-induced cardiomyopathy
34. Natriuretic peptides as markers of cardiotoxicity during doxorubicin treatment for non-Hodgkin's lymphoma
35. Acute neurohumoral and cardiovascular effects of idarubicin in leukemia patients
36. Cancer and cardiac mortality among 15-year survivors of cancer diagnosed during childhood or adolescence
37. Dexrazoxane in the prevention of doxorubicin-induced cardiotoxicity